FibroGen

FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. The Company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat, is an oral small molecule inhibitor of HIF prolyl hydroxylases in Phase 3 clinical development for the treatment of anemia in chronic kidney disease.

FibroGen's second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.

Company Growth (employees)
Type
Public
HQ
San Francisco, US
Founded
1993
Size (employees)
364 (est)
FibroGen was founded in 1993 and is headquartered in San Francisco, US

FibroGen Office Locations

FibroGen has an office in San Francisco
San Francisco, US (HQ)
409 Illinois St

FibroGen Data and Metrics

FibroGen Financial Metrics

FibroGen's revenue was reported to be $26.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

26.9 m

Net income (Q1, 2017)

(33.2 m)

EBIT (Q1, 2017)

(31.4 m)

Market capitalization (15-Aug-2017)

2.9 b

Cash (31-Mar-2017)

170.6 m
FibroGen's current market capitalization is $2.9 b.
USDFY, 2015FY, 2016

Revenue

180.8 m179.6 m

Revenue growth, %

(1%)

R&D expense

214.1 m187.2 m

General and administrative expense

44.4 m46 m

Operating expense total

258.5 m233.2 m

EBIT

(77.6 m)(53.7 m)

EBIT margin, %

(43%)(30%)

Interest expense

(11 m)(10.7 m)

Pre tax profit

(85.5 m)(61.8 m)

Income tax expense

242 k(71 k)

Net Income

(85.8 m)(61.7 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

16.3 m120.6 m19.5 m28.3 m89.3 m30.1 m26.9 m

R&D expense

50.5 m51.6 m52.1 m43.7 m52.4 m40.6 m46.7 m

General and administrative expense

10.5 m9.7 m11.2 m11.4 m10.4 m11.6 m11.5 m

Operating expense total

61 m61.2 m63.3 m55.1 m62.8 m52.2 m58.3 m

EBIT

(44.7 m)59.3 m(43.8 m)(26.8 m)26.5 m(22.1 m)(31.4 m)

EBIT margin, %

(274%)49%(224%)(95%)30%(73%)(117%)

Interest expense

(2.8 m)(2.8 m)(2.8 m)(2.8 m)(2.4 m)(2.8 m)(2.4 m)

Interest income

843 k707 k1.5 m

Pre tax profit

(46.6 m)57.3 m(45.1 m)(28.1 m)24.2 m(24 m)(33.1 m)

Income tax expense

(113 k)158 k60 k

Net Income

(46.4 m)57.1 m(45.1 m)(27.8 m)24.3 m(24.2 m)(33.2 m)
USDFY, 2015FY, 2016

Cash

153.3 m173.8 m

Accounts Receivable

15.4 m10.4 m

Inventories

4 m2.9 m

Current Assets

200.6 m266.5 m

PP&E

129 m123.7 m

Total Assets

470.6 m469.6 m

Accounts Payable

6.5 m6.2 m

Current Liabilities

67.2 m65.1 m

Total Liabilities

294.4 m

Additional Paid-in Capital

586.6 m625.9 m

Retained Earnings

(408.1 m)(469.7 m)

Total Equity

177.6 m155.8 m

Financial Leverage

2.7 x3 x
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

128.4 m236.5 m208.7 m141 m190.4 m198.3 m170.6 m

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m

Current Assets

155.4 m263.6 m232.6 m184 m252.3 m253.5 m256.6 m

PP&E

131.7 m130.5 m129.6 m127.6 m126.3 m124.8 m122.8 m

Total Assets

435.5 m541.4 m499.2 m442.5 m499.1 m486.2 m441.8 m

Accounts Payable

2.4 m3.9 m4.2 m1.5 m3.5 m2 m3 m

Current Liabilities

54 m63.5 m59 m58.3 m66.4 m61.7 m60.1 m

Additional Paid-in Capital

553.4 m565.2 m575 m593.9 m605.1 m614.8 m635 m

Retained Earnings

(368.7 m)(311.6 m)(356.7 m)(435.9 m)(411.6 m)(435.7 m)(502.9 m)

Total Equity

203.9 m272.9 m217.3 m157 m193.1 m178.3 m131.7 m

Financial Leverage

2.1 x2 x2.3 x2.8 x2.6 x2.7 x3.4 x
USDFY, 2015FY, 2016

Net Income

(85.8 m)(61.7 m)

Depreciation and Amortization

5.7 m6 m

Accounts Receivable

(2 m)5 m

Inventories

978 k1.1 m

Accounts Payable

2 m(298 k)

Cash From Operating Activities

(18.6 m)7.1 m

Purchases of PP&E

(2 m)(1.3 m)

Cash From Investing Activities

(5.9 m)6.6 m

Cash From Financing Activities

12.3 m6.7 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(46.4 m)57.1 m(45.1 m)(27.8 m)24.3 m(24.2 m)(33.2 m)

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m

Accounts Payable

2.4 m3.9 m4.2 m1.5 m3.5 m2 m3 m
USDY, 2017

Revenue/Employee

73.9 k

Financial Leverage

3.4 x

FibroGen Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

1

Facilities

2

Patent Portfolios

4

FibroGen Market Value History

FibroGen Revenue Breakdown

Traffic Overview of FibroGen

FibroGen Online and Social Media Presence

FibroGen Company Life and Culture

You may also be interested in